

PHASE APPROPRIATE
GMP FOR
BIOLOGICAL
PROCESSES

PRE-CLINICAL TO
COMMERCIAL PRODUCTION



Trevor Deeks
Editor

www.pda.org/bookstore

Phase Appropriate GMP for Biological Processes

**Pre-clinical to
commercial production**

Trevor Deeks
Editor

To order this book, please visit: go.pda.org/PGBP

PDA
Bethesda, MD, USA
DHI Publishing, LLC
River Grove, IL, USA

www.pda.org/bookstore

10 9 8 7 6 5 4 3 2 1

ISBN: 978-1-942911-17-3

Copyright © 2018 Trevor Deeks

All rights reserved.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The authors have made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



Connecting People, Science and Regulation®



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

PDA Global Headquarters

Bethesda Towers, Suite 600
4350 East-West Highway
Bethesda, MD 20814
United States
www.pda.org/bookstore
001-301-986-0293

Davis Healthcare International Publishing, LLC

2636 West Street
River Grove
IL 60171
United States
www.DHIBooks.com

www.pda.org/bookstore

CONTENTS

I	INTRODUCTION	I
	<i>Trevor Deeks</i>	
2	WHAT IS PHASE APPROPRIATE GMP? THE REGULATORY BACKGROUND AND CURRENT EXPECTATIONS	5
	<i>Trevor Deeks</i>	
	Introduction	5
	What is Phase Appropriate GMP?	7
	The Regulatory Background	9
	Enforcement	11
	Risk-Based Approach	14
	The Clinical Supply-Chain	16
	Best Practices	17
	Obstacles to Implementing Best Practices	19
	Summary	20
	References	20
	About the Author	23

3	IMPACT OF THE EU CLINICAL TRIALS DIRECTIVE AND THE ROLE OF THE QP	25
	<i>Mark Slattery</i>	
	Introduction	25
	EU GMP Requirements before the Clinical Trials Directive	26
	Impact of Clinical Trial Directive Implementation in EU	36
	Regional Differences in Enforcement for Clinical Trial GMP	47
	Regional Differences in Expectations for Clinical Trial GMP	53
	Future Developments in EU GMP for Clinical Trials	63
	References	66
	About the Author	67
4	SYSTEMS AND SYSTEM INTEGRITY IN THE ANALYTICAL LABORATORY	69
	<i>Siegfried Schmitt</i>	
	Introduction	69
	The Need for Documented Evidence	70
	Automation, a Necessity, Not a Nice-to-Have	72
	Systems and Data	74
	Managing the Body of Knowledge	80
	Preparing/Selecting Data for Inclusion in Submissions	82
	Data Retention and Retrievability	83
	Summary	88
	References	88
	About the Author	89
5	PHASE APPROPRIATE GMP IN THE LABORATORY	91
	<i>John Duguid</i>	
	Introduction	91
	Specifications	93
	Development	95
	Qualification	97
	Validation	99
	Technology Transfer	102
	Lifecycle Management	104
	Stability	106
	Conclusion	108
	References	108
	About the Author	110

6	PHASE-BASED APPROACH TO QUALITY ASSURANCE IN PHARMACEUTICAL MANUFACTURING – BIG PHARMA PERSPECTIVE	111
	<i>David Grote</i>	
	Introduction	111
	Overview of the Typical Process of Biopharmaceutical Development	112
	Early R&D and Pre-clinical Development	114
	Pre-clinical Toxicology Studies and Test Article Quality Assurance	116
	Clinical Material Quality Assurance	118
	Setting Acceptance Criteria for Early Clinical Production	119
	Phase 1	119
	Phase 2	123
	Phase 3	126
	Summary	128
	References	129
	About the Author	130
7	PHASE APPROPRIATE cGMPs: THE VIRTUAL COMPANY	131
	<i>Paul Steiner and Trevor Deeks</i>	
	Introduction	131
	The Challenges of a Virtual Company	133
	Essentials of a QMS for the Virtual Company	136
	Standard Operating Procedures	138
	Training	139
	Deviation Investigations and CAPA	140
	Change Control	141
	Self Inspections	142
	Continuous Improvement	143
	Quality Agreements	143
	Validation	146
	Analytical Methods Validation vs. Qualification	148
	The Evolution of the Phase Appropriate QMS from Phase 2 to Commercial Manufacturing	152
	Management Review of Contractors	155
	Complaints, Pharmacovigilance and Annual Product Review	158
	Summary	160
	References	161
	About the Authors	163

8	DEVIATIONS, CHANGE CONTROL, PROCESS IMPROVEMENTS	165
	<i>Sue Schniepp</i>	
	Introduction	165
	Deviation Investigations	167
	Change Control	169
	Types of Changes	170
	Records, Documents and Change Control	172
	Material Controls	174
	Facility and Equipment Controls	180
	Production and Process Controls	180
	Regulatory Requirements	184
	References	189
	About the Author	190
9	CREATING A CULTURE AND SYSTEM FOR LEARNING WHEN USING A PHASE APPROPRIATE MODEL	191
	<i>James Vesper</i>	
	Tacit and Explicit Knowledge	193
	Sticky and Leaky Knowledge	194
	Explicit/Tacit and Sticky/Leaky: Consultants and Contractors	196
	Organizations with Strong Learning Cultures	197
	Establishing and Nurturing a Learning Culture	198
	What a Learning Culture Would Include to Meet	
	Regulatory Expectations	211
	Regulations and Expectations	212
	Competency-based Training	218
	The Importance of Knowing Why	221
	Conclusion	222
	References	222
	About the Author	225
10	CELL LINE CHARACTERIZATION	227
	<i>Sandra K. Dusing, Kathy Martin Remington, Marian L. McKee, Audrey Chang</i>	
	Introduction	227
	Cell Line Characterization	228
	Sourcing/History/Generation of Cell Banks	228
	Cell Banking	230

	Characterization and Testing of Cell Substrates	231
	Microbial Agents	232
	Viruses	233
	Evolving Testing Tools	236
	Summary	237
	References	238
	About the Authors	240
11	CONSIDERATIONS FOR VIRAL CLEARANCE STUDIES	241
	<i>Kathryn Martin Remington and Kate Smith</i>	
	Introduction	241
	Viruses for Clearance Studies	242
	Viral Clearance Studies in Clinical Trials Material	
	Versus Product Licensure	247
	Virus Spike Preparations	248
	Virus Detection Assays	250
	Pre-Study Assays	251
	Scale Down Model	254
	Spiking Studies	274
	Chromatography Steps	275
	Inactivation Methods	283
	Determining Optimal Viral Reduction	292
	Reduction Expectations	295
	Summary of Phase Appropriate Expectations	296
	References	298
	About the Authors	305
12	THE IMPACT OF SINGLE-USE SYSTEMS ON THE APPLICATION OF PHASE APPROPRIATE GMP IN BIOPROCESSING	307
	<i>Trevor Deeks and Jeff Blake</i>	
	Introduction	307
	Historical Development of Bioreactors and SU Systems	313
	The Cost of Quality	317
	What are the Quality Factors to Consider for SU Bioreactors?	319
	Validation of SU Bioreactors	322
	SU Systems for Downstream Processing	331
	Extractables and Leachables	333
	The Impact of SU Systems on Phase Appropriate GMP	334

Summary	335	
References	337	
About the Authors	339	
13	REGENERATIVE MEDICINE ADVANCED THERAPIES: PHASE APPROPRIATE GOOD MANUFACTURING PRACTICES	341
	<i>Gary C. du Moulin</i>	
Introduction	341	
Overview of Regenerative Medicine Advanced Therapy Products	344	
Regulation of Regenerative Medicine Advanced Therapy Products	348	
Factors that Affect Safety and Efficacy: Cells as Products	354	
Providing Benefit to RMAAT Development: Quality by Design	357	
Phase Appropriate Requirements for Production of RMAAT Products	360	
Supply Chain for Components and Reagents Used in RMAAT Product Manufacturing	367	
Clinical and Manufacturing Challenges: Control of Manufacturing Processes	372	
Product Characterization and Process Control Strategies	376	
Paths to Commercialization	381	
Conclusions	383	
References	385	
About the Author	397	
14	MICROBIOLOGICAL CONTROL AND TESTING FOR PHASE APPROPRIATE GMP	399
	<i>Tim Sandle</i>	
Introduction	399	
Role of the Microbiologist	402	
Risk Assessment	403	
Cleaning Validation	419	
Raw Materials	420	
Intermediate Product Testing	420	
End Product Testing	425	
Method Validation	430	
Summary	433	
References	435	
About the Author	437	

15	THE EVOLUTION OF PROCESS VALIDATION	439
	<i>Karen Zink McCullough</i>	
	Background	439
	Stage 1: Process Design	445
	Stage 2: Process Qualification	451
	Stage 3: Continued Process Verification	458
	The Pharmaceutical Quality System: The Super Glue of Process Validation	461
	Summary	469
	References	470
	About the Author	471
16	STERILITY ASSURANCE IN EARLY PHASE DEVELOPMENT	473
	<i>Tim Sandle</i>	
	Introduction	473
	Sterility Assurance	474
	Facility Design	476
	Sterilized Components and Equipment	481
	Sterile Filtration	491
	Media Fills for Aseptically Filled Products	493
	Summary	504
	References	505
	About the Author	507
	Index	509